1220219-19-1 Usage
Sure, here's the information organized into a list
1. Chemical Name: 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanenitrile
2. Chemical Structure:
It consists of a propanenitrile group attached to a phenyl ring, which is connected to a 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl group.
3. Applications:
Pharmaceutical Research: Used in the synthesis of pharmaceutical compounds due to its versatile chemical structure.
Agrochemical Research: Finds applications in the synthesis of agrochemicals for agricultural purposes.
Material Science: Used in the development of novel materials due to its unique properties.
4. Role in Organic Synthesis:
Building Block: Serves as a crucial building block for the synthesis of various organic compounds.
Versatility: Its unique structure allows it to participate in a variety of chemical reactions, enhancing its utility in organic synthesis.
3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanenitrile's significance lies in its versatility and utility across multiple fields of chemistry, including pharmaceuticals, agrochemicals, and material science, owing to its unique chemical structure.
Check Digit Verification of cas no
The CAS Registry Mumber 1220219-19-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,0,2,1 and 9 respectively; the second part has 2 digits, 1 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 1220219-19:
(9*1)+(8*2)+(7*2)+(6*0)+(5*2)+(4*1)+(3*9)+(2*1)+(1*9)=91
91 % 10 = 1
So 1220219-19-1 is a valid CAS Registry Number.
1220219-19-1Relevant academic research and scientific papers
TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME
-
Page/Page column 385, (2011/10/13)
Trycyclic compounds are provided. These compounds are PBK inhibitors, and are useful for the treatment of PBK related diseases, including cancer.
PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS
-
Page/Page column 72-73, (2008/06/13)
The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.
